



**2022 Annual General Meeting
Board of Director Candidates**

Albert Cha, M.D., Ph.D. (Current Board Member)

Albert Cha, M.D., Ph.D. has served as a member of the board of directors since November 2014 and as the Chairman of our board of directors since May 2021. Dr. Cha is a Managing Partner with Frazier Life Sciences. He previously was a managing partner at Vivo Capital LLC, a healthcare investment firm, where he has served in various positions, most recently as a managing partner. Dr. Cha currently serves as a member of the board of directors of KalVista Pharmaceuticals, Inc. In addition, Dr. Cha has previously served as a member of the board of directors of Aclaris Therapeutics, a publicly traded dermatology company, BioForm Medical, Inc., a publicly traded medical aesthetics company, Carbylan Therapeutics, a publicly traded orthopedics company, Sierra Oncology, Inc., a publicly traded oncology company, Biohaven Pharmaceutical Holding Company Ltd, a publicly traded clinical-stage biopharmaceutical company targeting neurological diseases and Menlo Therapeutics, Inc., a publicly traded late-stage biopharmaceutical company focused on the treatment of pruritus. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.

Lars Holtug, M.Sc. (Current Board Member)

Lars Holtug, M.Sc. has served as a member of our board of directors since November 2018. Mr. Holtug was a partner at PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab ("PwC") from 1993 to 2015. Mr. Holtug also currently serves as chairman of Gaming Investment A/S, a gaming solutions provider, and its eleven subsidiaries, and of MTI Caretag Invest A/S, a company investing in healthcare technology. Mr. Holtug also currently serves as a board member of Frida Forsikring Agentur A/S, Domus Forsikring A/S and Evaxion Biotech A/S, as well as the Audit Committee Chair of the board of Domus Forsikring A/S and Evaxion Biotech A/S. Previously, he was Chairman of PwC in Denmark from 2005 to 2009. From 2004 to 2015, Mr. Holtug was a member of the Danish Commercial Appeals Board (Erhvervsankenaevnet) and a board member of the Danish Company law association (Dansk Forening for Selskabsret). He was also a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (Foreningen af Statsautoriserede Revisorer) from 1998 to 2002, and a member of the Auditing Standards Board from 1993 to 1998. Mr. Holtug holds an M.Sc. from Copenhagen Business School and is educated as a state authorized public accountant in Denmark.

Rafaèle Tordjman, M.D., Ph.D. (Current Board Member)

Rafaèle Tordjman, M.D., Ph.D. has served as a member of our board of directors since November 2021, and previously served on our board of directors from 2007 until 2017. In 2018, Dr. Tordjman founded Jeito Capital, an independent investment company dedicated to biopharma/biotech to establish a model of continuous financing and to invest in the next generation of leaders in medical innovation. Dr. Tordjman was a Special Advisor at Sofinnova Partners from 2001 until March 2017, where she also served as Managing Partner specializing in life sciences investments from January 2011 to February 2017. Dr. Tordjman currently serves as the Chairperson of the board of InnoSkel, a biotechnology company, and Alentis Therapeutics, a clinical-stage biopharmaceutical company. Dr. Tordjman has also served on the boards of directors at several life sciences companies, including ObsEva SA, a Nasdaq-listed biopharmaceutical company, NuCana plc, a Nasdaq-listed clinical-stage pharmaceutical company, DBV Technologies SA, a publicly traded company specializing in allergy therapies, Flexion Therapeutics, Inc., a publicly traded company in clinical-stage pharmaceuticals, PregLem, a company specializing in reproductive female medicine, Lysogene, a public biopharmaceutical company developing treatments against central nervous system and genetic diseases, Medday Pharmaceuticals, a French company specializing in therapies against neurodegenerative diseases, and ENYO Pharma SA, a clinical stage biopharmaceutical company. Previously, Dr. Tordjman was a research scientist at the Institut National de la Santé et de la Recherche Médicale (INSERM) in Cochin Hospital, Paris, France. Dr. Tordjman has also practiced as a medical doctor, specializing in

clinical hematology and internal medicine. Dr. Tordjman received an M.D. and completed a fellowship in hematology and internal medicine at the Paris University Hospitals, France. She received a Ph.D. in hematopoiesis and angiogenesis from and completed a post-doctoral fellowship in immunology at the University of Paris VII.